Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.62 - $5.05 $18,798 - $58,600
11,604 Added 111.74%
21,989 $36,000
Q1 2024

May 10, 2024

BUY
$4.82 - $8.26 $50,055 - $85,780
10,385 New
10,385 $53,000
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $178,386 - $241,527
44,155 New
44,155 $187,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.